KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Net Margin: 2009-2025

Historic Net Margin for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to 49.46%.

  • Halozyme Therapeutics' Net Margin rose 223.00% to 49.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 47.91%, marking a year-over-year increase of 648.00%. This contributed to the annual value of 43.74% for FY2024, which is 978.00% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Net Margin of 49.46% as of Q3 2025, which was down 2.44% from 50.70% recorded in Q2 2025.
  • Halozyme Therapeutics' Net Margin's 5-year high stood at 186.99% during Q3 2021, with a 5-year trough of 14.89% in Q2 2022.
  • For the 3-year period, Halozyme Therapeutics' Net Margin averaged around 40.98%, with its median value being 40.30% (2024).
  • Its Net Margin has fluctuated over the past 5 years, first soared by 13,155bps in 2021, then slumped by 15,749bps in 2022.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Net Margin stood at 65.46% in 2021, then slumped by 3,367bps to 31.79% in 2022, then skyrocketed by 533bps to 37.12% in 2023, then spiked by 886bps to 45.98% in 2024, then soared by 223bps to 49.46% in 2025.
  • Its Net Margin was 49.46% in Q3 2025, compared to 50.70% in Q2 2025 and 44.59% in Q1 2025.